Subtitle
Long-term clinical outcomes of patients receiving proton beam therapy for caudate lobe hepatocellular carcinoma.
Subtitle
Long-term clinical outcomes of patients receiving proton beam therapy for caudate lobe hepatocellular carcinoma.
Proto therapy Time
July 2021
Executive summary
Thirty patients with caudate lobe HCC were treated to a total doses of 55 to 77 (median 72.6) GyRBE. The median follow-up period was 37.5 months. The OS rates at 1-, 3- and 5-year were 86.6%, 62.8% and 46.1%, respectively, and the LC rates of 100%, 85.9% and 85.9%, respectively. No grade 3 or worse adverse events were observed. PBT is effective and safe for the treatment of caudate HCC, should therefore be considered a feasible option for intervention in patients with this disease.
Key content topics
Top cancer treatments
Related contents
Proton Therapy Publication
November 2023
Proton beam radiotherapy versus transarterial chemoembolization for hepatocellular carcinoma: Results of a randomized clinical trial.
Proton Therapy Publication
March 2023
Proton versus photon radiation therapy: A clinical review.
Proton Therapy Publication
August 2022
Proton Beam Therapy for Esophageal Cancer.
Webinar
April 22, 2022
The State of Proton Therapy in the U.S.
James
Metz
Webinar
April 22, 2022
Expanding Proton Therapy to Community Oncology Practices
Barbara
McAneny
Webinar
December 2021
Ongoing Trials and Current Evidence for proton therapy
Daniela
Alterio
Proton Therapy Publication
July 2021
PBT in rectal cancer
Proton Therapy Publication
June 2021
PTCOG Head and Neck Subcommittee Consensus Guidelines on Particle Therapy for the Management of Head and Neck Tumors
Proton Therapy Publication
April 2020
Particle therapy in Europe. A review article looked at the status of clinical utilization of particle therapy such as protons or heavier ions in Europe.